Targeting the CARM1-NFIB pathway to treat small cell lung cancer
Official title: Mechanisms of action and therapeutic targeting of the CARM1-NFIB axis in small cell lung cancer
Funded at University of Tx Md Anderson Can Ctr · NIH-11364113 · Data updated 2026-11-12
This project studies how a specific protein interaction drives small cell lung cancer and tests new ways to block it to help patients.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Tx Md Anderson Can Ctr NIH-funded |
| Lab location | 1 site (Houston, United States) |
| Project start | July 1, 2023 |
| Project end | June 30, 2028 |
| Funding year | 2026 |
| Award (this year) | $651,402 |
| NIH project number | 5R01CA272843-04 |
| Project ID | NIH-11364113 on NIH RePORTER |
Who could benefit from this research
✓Could help
Patients with small cell lung cancer or a history of SCLC could benefit from future therapies arising from this work.
✕Less likely to help
Patients with cancers not driven by the CARM1-NFIB axis or who cannot access targeted therapies may not benefit.
What this research studies
Scientists will explore how CARM1 modifies NFIB to promote cancer growth and spread in small cell lung cancer using advanced mouse models and cellular studies. They will map the signaling steps in this CARM1/NFIB/TRIM29 axis and test potential inhibitors in preclinical systems. The goal is to identify a therapeutic strategy that could slow or stop disease progression and improve outcomes for patients with SCLC. The work combines genetic mouse models, molecular analysis, and preclinical testing to translate findings toward targeted therapies.
Why it matters
Potential benefit: If successful, this research could lead to targeted treatments that slow SCLC progression and extend survival.
How similar studies have gone: Previous studies show that targeting similar molecular pathways can impact tumor growth in animal models, supporting the approach's potential.
Where this research is happening
-
University of Tx Md Anderson Can Ctr
Houston, United States Active
Researchers
- Principal investigator: Mazur, Pawel K. — University of Tx Md Anderson Can Ctr
- Study coordinator: Mazur, Pawel K.
Related research
Other NIH-funded projects on the same topics.
-
ABL kinase signaling and DNA collisions in small cell lung cancer
A drug target study in small cell lung cancer explores how blocking ABL kinase affects conflicts between transcription and DNA replication, which could influence tumor growth and survival.
-
XRN1 as a potential therapy target in lung cancer
A scientist-led program will study a cellular gene called XRN1 to see if turning it off can help treat non-small cell lung cancer.
-
Intermittent fasting with PD-1 inhibitors for non-small cell lung cancer
This grant tests whether a fasting-mimicking diet can boost the effectiveness of PD-1 inhibitors for people with non-small cell lung cancer.
-
Targeting STRAP to curb NSCLC spread with nanoparticle therapy
Aimed at non-small cell lung cancer, this grant tests how blocking a protein called STRAP with nanoparticles could slow cancer spread and make chemotherapy work better.
-
Modeling tumor differences to guide new treatments for resistant small cell lung cancer
A study aims to understand why some small cell lung cancer tumors resist treatment and use those insights to develop new targeted therapies.
-
TP53-mutant NSCLC: how epigenetic viral mimicry could boost immune therapy
A research grant exploring how p53 mutations in non-small cell lung cancer affect responses to a viral mimicry-based epigenetic therapy, with the goal of improving immune therapy outcomes for patients.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.